MHRA marketing authorisation granted for Eli Lilly’s Verzenios as early breast cancer treatment
Authorisation of the treatment is based on results from the phase 3 trial
Read More
Tag: Verzenios
NICE recommends Eli Lilly’s breast cancer drug Verzenios
Cost-effectiveness watchdog initially rejected the drug in February
Read More
NICE rejects Lilly’s Verzenios for advanced breast cancer
CDK4 & 6 inhibitor has been available as part of a Cancer Drugs Fund (CDF) managed access agreement
Read More
NICE approval for Verzenios in metastatic breast cancer
The National Institute for Health and Care Excellence has recommended Eli Lilly’s Verzenios in combination with an aromatase inhibitor as treatment option for locally advanced or metastatic breast cancer
Read More
NICE rejects Lilly’s breast cancer drug Verzenios
As it stands Eli Lilly’s Verzenios will not be routinely funded on the NHS for breast cancer, as cost-regulators have now issued draft guidelines rejecting the drug.
Read More
EU nod for Lilly’s new breast cancer drug
Eli Lilly’s CDK 4 and 6 inhibitor Verzenios has been approved in Europe for the treatment of certain metastatic breast cancers.
Read More
- King’s Doctoral Training Centre to investigate MS symptom management
- Agenda announced for FlyPharma Vienna 2024
- Therapy reprogrammes immune cells to shrink prostate and bladder cancers
- Researchers combine herpes virus with cancer vaccine to treat brain cancer in children
- UK MRC and AstraZeneca partner for translational clinical research
